Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients aged 40-75 years with diagnosis of mild or moderate COPD
Current or X-smokers with a smoking history of \>10 pack-years.
Screening ipratropium post-bronchodilation FEV1 at 1 h post-dose will be greater than 50% of the normal predicted FEV1 value.
You may not be if
Patients who can not comply with the following washout periods for standard
COPD treatments as follows should be excluded:
Short-acting bronchodilators
Long-acting bronchodilators
Inhaled steroids
Clareo Health | Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.
